About Viz.ai
Viz.ai news and updates
Viz.ai received financing of $100M in Series D funding round on Apr 7th 22'.
((Getty Images)) After an FDA clearance earlier this year for its artificial intelligence-powered program designed to spot dangerous aneurysms, Viz.ai has raised $100 million to continue expanding into other conditions.
Jan 1, 2022 | fiercebiotech.comViz.ai launched AI-driven solutions for aortic disease on Apr 7th 21'.
Over the past year, Viz.ai launched AI-driven solutions for aortic disease, pulmonary embolism, cerebral aneurysms, and is 510(k) pending for subdural hematoma.
Jan 1, 2021 | hitconsultant.netViz.ai integrates with Hyperfine
Viz.ai is integrating its LVO AI technology with Hyperfine's Swoop MR imaging scanner to expedite stroke diagnostic care.
Jan 1, 2022 | dotmed.comViz.ai partnered with Hyperfine Inc. on Jul 26th 22'.
Viz.ai, the leading AI-powered disease detection and intelligent care coordination platform, announced today it is partnering with Hyperfine, Inc. (Nasdaq: HYPR), creator of the first FDA-cleared point-of-care magnetic resonance imaging (MRI) device, Swoop ®.
Jan 1, 2022 | hyperfine.ioViz.ai hires Jieun Choe as chief marketing officer
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has named life sciences veteran Jieun Choe as chief marketing officer (CMO).
Oct 25, 2022 | bakersfield.comViz.ai partnered with Illuminate on Nov 16th 22'.
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a partnership with Illuminate, Inc., an industry leader in the development of proprietary natural language processing (NLP) and AI software that discovers at-risk patients from electronic medical records (EMR), assesses disease severity, and facilitates follow-up surveillance for a variety of diseases.
Nov 15, 2022 | businesswire.comViz.ai partnered with Vastrax on Nov 16th 22'.
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic partnership with Vastrax, the leading full-service, vascular clinical research organization (CRO).
Nov 16, 2022 | businesswire.comViz.ai launches AI software that discovers at-risk patients from electronic medical records
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, announced a partnership with Illuminate, an industry leader in the development of proprietary natural language processing (NLP) and AI software that discovers at-risk patients from electronic medical records (EMR), assesses disease severity, and facilitates follow-up surveillance for a variety of diseases.
Nov 15, 2022 | aithority.comViz.ai launched data from a large aortic dissection artificial intelligence real-world study on Nov 18th 22'.
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new data from a large aortic dissection artificial intelligence real-world study that supports the use of its artificial intelligence technology for the detection of suspected aortic dissection.
Nov 18, 2022 | businesswire.comViz.ai launched algorithms and expanded features for Viz RECRUIT clinical trial platform on Feb 1st 20'.
In February 2020, Viz.ai announced new algorithms and expanded features for its Viz RECRUIT clinical trial platform, which offers new algorithms for intracerebral haemorrhage detection, aneurysm detection, and Ischemic Core Volumes.
Nov 17, 2022 | clinicaltrialsarena.comViz.ai hires Kevin Abrams as co-chairs for the board
Viz.ai appointed Dr. Kevin Abrams and Dr. Suzie Bash as co-chairs for the board.
Nov 28, 2022 | massdevice.comViz.ai recognized as Comparably Best Place to Work Awards for Best Company Culture and Best Company for Diversity in 2022
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has received two additional Comparably Best Place to Work Awards for Best Company Culture and Best Company for Diversity in 2022.
Dec 15, 2022 | eagletribune.com